Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failure of chemotherapy, CAR-T therapy, and PD-1 blockade
- 1Department of Hematology, Endocrinology, and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan, Department of Hematopoietic Cell Therapy, Niigata University Medical and Dental Hospital, Niigata, Japan, Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, Division of Pathology, Kurume University, Fukuoka, Japan
Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) typically responds to chemotherapy, and immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab have shown promise in relapsed or refractory cases. However, the sequential use of multiple immunotherapies for PMBCL remains poorly characterized. Here, we report a case of a 19-year-old female with PMBCL involving the mediastinum and multiple extranodal sites. After a partial response to chemotherapy, she developed a central nervous system relapse that responded to high-dose methotrexate, and the number of regrowing mediastinal lesions was reduced by radiotherapy. Subsequently, new hepatic lesions that were refractory to both CAR-T therapy and pembrolizumab emerged. Following localized liver radiotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed, resulting in complete response. Early post-transplant, she developed a hepatitis variant of acute graft-versus-host disease, which may have reflected a graft-versus-lymphoma (GVL) effect. Despite maintaining response, the patient died one year later form a disseminated infection with multitriazole-resistant Aspergillus fumigatus. This case highlights both the potential curative role and the substantial risks of allo-HSCT in PMBCL refractory to multiple immunotherapies. The pre-transplant use of pembrolizumab and localized radiotherapy may influence transplant outcomes and warrants further investigation.
Related
- TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351
- Addition of thiotepa to total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma: a propensity score-matched retrospective study.
- BLINATUMOMAB AS A BRIDGE THERAPY TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY TO MULTIPLE CHEMOTHERAPY REGIMENS: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE NEGATIVITY AND IMPACT ON OUTCOME
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
BibTeX
@article{suwabe2026allogeneic,
title = {{Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failure of chemotherapy, CAR-T therapy, and PD-1 blockade}},
author = {Tatsuya Suwabe and Yuri Furuyama and Ayako Kawakami and Takumu Tsuchida and Masaki Mitobe and Hodaka Yonezawa and Takayuki Katagiri and Kyoko Fuse and Yasuhiko Shibasaki and Takashi Ushiki and Masayoshi Masuko and Wataru Munakata and Hiroaki Miyoshi and Koichi Ohshima and Hirohito Sone and Jun Takizawa},
journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
year = {2026},
month = jul,
doi = {10.3960/jslrt.26007},
url = {https://doi.org/10.3960/jslrt.26007},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failure of chemotherapy, CAR-T therapy, and PD-1 blockade
AU - Tatsuya Suwabe
AU - Yuri Furuyama
AU - Ayako Kawakami
AU - Takumu Tsuchida
AU - Masaki Mitobe
AU - Hodaka Yonezawa
AU - Takayuki Katagiri
AU - Kyoko Fuse
AU - Yasuhiko Shibasaki
AU - Takashi Ushiki
AU - Masayoshi Masuko
AU - Wataru Munakata
AU - Hiroaki Miyoshi
AU - Koichi Ohshima
AU - Hirohito Sone
AU - Jun Takizawa
PY - 2026
DA - 2026/07/30
JO - Journal of Clinical and Experimental Hematopathology : JCEH
DO - 10.3960/jslrt.26007
UR - https://doi.org/10.3960/jslrt.26007
AB - Primary mediastinal large B-cell lymphoma (PMBCL) typically responds to chemotherapy, and immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab have shown promise in relapsed or refractory cases. However, the sequential use of multiple immunotherapies for PMBCL remains poorly characterized. Here, we report a case of a 19-year-old female with PMBCL involving the mediastinum and multiple extranodal sites. After a partial response to chemotherapy, she developed a central nervous system relapse that responded to high-dose methotrexate, and the number of regrowing mediastinal lesions was reduced by radiotherapy. Subsequently, new hepatic lesions that were refractory to both CAR-T therapy and pembrolizumab emerged. Following localized liver radiotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed, resulting in complete response. Early post-transplant, she developed a hepatitis variant of acute graft-versus-host disease, which may have reflected a graft-versus-lymphoma (GVL) effect. Despite maintaining response, the patient died one year later form a disseminated infection with multitriazole-resistant Aspergillus fumigatus. This case highlights both the potential curative role and the substantial risks of allo-HSCT in PMBCL refractory to multiple immunotherapies. The pre-transplant use of pembrolizumab and localized radiotherapy may influence transplant outcomes and warrants further investigation.
SN - 1346-4280
SN - 1880-9952
ER -